Phase I/IIa Dose Ranging CHRONVAC-C® Study in Chronic HCV Patients

Inclusion Criteria: * Male or female patient 18 -65 years of age with a known chronic hepatitis C infection. * Genotype 1 infection. * Viral load equal to or less than 800.000 IU/mL. * BMI less than 30. * Considered probable that the deltoid muscles (left and right) of the patient will be reached at vaccination using a 12.7 mm cannula for injection and a 15 mm applicator tip for electroporation. * Written informed consent obtained, and a copy provided to the patient. * Patient legally competent and able to communicate effectively with the study personnel. * Patient likely to co-operate and attend the clinic at the appointed times during the study. Exclusion Criteria: * Patient having clinically significant concomitant diseases other than HCV in the medical history to the discretion of the investigator. * Patient having clinically significant findings on physical examination, vital signs, ECG or clinical laboratory evaluations to the discretion of the investigator. * Patient having clinical or biochemical signs of cirrhosis. * Positive hepatitis B surface antigen (HBsAg). * Positive HIV antigen or antibody test. * Patient having an ongoing and/or known viral infection other than HCV that requires treatment and/or special medical intention. * Patient having received previous treatment for HCV. * Radiation therapy or cytotoxic chemotherapeutic agents within 4 weeks prior to the first dose of study drug. * Treatment with immunomodulating agents such as systemic corticosteroids, IL-2, IFN-alpha, IFN-beta, IFN-gamma within 4 weeks prior to the first dose of study drug. * Treatment with NSAID within 10 days of the first dose of study drug. * Immunization within 30 days of the first dose of the study drug. * Patient having received an investigational drug product, or been enrolled in other investigational drug protocols within a period of 30 days prior to receiving the first dose of the study drug. * Prior treatment with DNA therapy. * Known allergy towards vaccines. * Known abuse of alcohol, drugs or pharmaceuticals. * History, signs or symptoms of a cardiac disease. * Presence of an implantable pacemaker. * Any metal implants within the treatment areas (close to the right and/or left deltoid muscles). * Diagnoses of a serious psychiatric illness which may influence study participation. * Female patient who is breast feeding. * Female patient not clinically sterile (hysterectomy, tubal ligation or postmenopausal (amenorrhea \> 1 year and FSH \> 30 mU/ml) OR if not clinically sterile unwilling to use a reliable contraception method. * Patient with a positive urine pregnancy test. * Male patient unwilling to use condom for active prevention of pregnancy from first vaccination to 4 months after last injection. * Patient or their immediate families being an investigator or site personnel directly affiliated with this study. Immediate family is defined as a spouse, parent, child or sibling, whether biologically or legally adopted.